Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

434.52 +0.98 (+0.23%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9

...

73 74 Next >

Which S&P500 stocks are moving on Tuesday? ↗

March 10, 2026

Via Chartmill

Top S&P500 movers in Tuesday's pre-market session ↗

March 10, 2026

Via Chartmill

Nasdaq, S&P 500 Futures Turn Green On Iran War De-Escalation Signals: Why NVDA, ORCL, JOBY, VRTX, ZVRA Are On Traders' Radar Today ↗

March 10, 2026

Data from Stocktwits indicated that retail sentiment on SPY and QQQ was stabilizing.

Via Stocktwits

VRTX Soars In Extended Hours After Experimental Drug Shows Positive Changes In Autoimmune Kidney Disease ↗

March 09, 2026

The company said that patients treated with povetacicept achieved a 52.0% reduction from baseline in urine protein to creatinine ratio at week 36, meeting the study’s key goal.

Via Stocktwits

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Shows High Technical and Setup Ratings for Potential Breakout ↗

February 28, 2026

Via Chartmill

Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy

March 09, 2026

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Buying This 1 Biotech Stock Now Could Help Make You a Multimillionaire Retiree ↗

March 08, 2026

The company has performed well over the long run.

Via The Motley Fool

Topics Intellectual Property Retirement

Vertex to Participate in Upcoming March Investor Conferences

March 05, 2026

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures

March 05, 2026

From Vertex Pharmaceuticals Incorporated

Via Business Wire

2 Biotech Giants to Buy in 2026 ↗

March 05, 2026

Both of these players are leaders in their fields.

Via The Motley Fool

Topics Intellectual Property

Forget CRISPR Therapeutics: This Gene‑Editing Player Already Boasts the Profits It Dreams Of ↗

March 04, 2026

These two biotechs have a lot in common. Their differences are even more pronounced.

Via The Motley Fool

Is CRISPR Therapeutics Stock Too Risky to Buy Right Now? ↗

March 02, 2026

CRISPR isn't profitable, but it does have an approved gene therapy treatment with loads of potential.

Via The Motley Fool

2 Top Healthcare Stocks to Buy in February ↗

February 26, 2026

Patience should pay off with these two healthcare giants.

Via The Motley Fool

Forget Centessa Pharmaceuticals: This Rare‑Disease Specialist Has a Superior Portfolio and Pipeline ↗

February 26, 2026

One of these is not like the other.

Via The Motley Fool

Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics

February 25, 2026

In a definitive move to dominate the next frontier of immunology and oncology, Eli Lilly and Company (NYSE: LLY) announced on February 9, 2026, its acquisition of Orna Therapeutics for a total...

Via MarketMinute

Topics Intellectual Property

2 Nasdaq 100 Stocks Worth Your Attention and 1 We Question

February 24, 2026

The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing...

Via StockStory

The Ultimate Biotech Stock to Buy With $500 Right Now ↗

February 24, 2026

This biotech powerhouse could maintain its strength for the long term.

Via The Motley Fool

Topics Intellectual Property

Could Vertex Stock Help Turn $100,000 Into $1 Million by 2036? ↗

February 22, 2026

Even a great stock has a ceiling.

Via The Motley Fool

Topics Intellectual Property

The Gene‑Therapy Breakthrough Story You'll Be Mad You Ignored at These Prices ↗

February 20, 2026

Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.

Via The Motley Fool

Topics ETFs

CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows ↗

February 19, 2026

Via MarketBeat

5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q4 Earnings Call

February 19, 2026

Vertex Pharmaceuticals delivered fourth quarter results that outpaced Wall Street's revenue expectations, driven by continued expansion in cystic fibrosis therapies and early contributions from...

Via StockStory

Topics Earnings

1 S&P 500 Stock with Competitive Advantages and 2 We Turn Down

February 18, 2026

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some...

Via StockStory

Topics Stocks

Vertex: The Quiet Biotech Compounder I'd Happily Hold Through Any Market Crash ↗

February 18, 2026

Vertex has the revenue power to excel during any market environment.

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3

February 17, 2026

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline

February 17, 2026

As of February 17, 2026, Moderna, Inc. (NASDAQ:MRNA) finds itself at a pivotal crossroads in its corporate evolution. Long defined by its meteoric rise during the COVID-19 pandemic, the Cambridge-based...

Via Finterra

Topics Economy Intellectual Property

Sanofi Tightens Grip on Ocular Therapeutix with Revised Bid as Pivotal SOL-1 Trial Results Loom

February 16, 2026

In a move that could reshape the multi-billion-dollar retinal disease market, French pharmaceutical giant Sanofi (NASDAQ: SNY) has reportedly returned to the negotiating table with a significantly...

Via MarketMinute

Moderna, Vertex Pharmaceuticals, Integra LifeSciences, Baxter, and Molina Healthcare Shares Are Soaring, What You Need To Know

February 13, 2026

A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a...

Via StockStory

Topics Economy

The Blastoff-Ready Biotech Stock You'll Kick Yourself for Not Buying in 2026 ↗

February 13, 2026

2026 could be a big year for this company.

Via The Motley Fool

Top S&P500 movers in Friday's session ↗

February 13, 2026

Via Chartmill

Why CRISPR Therapeutics Stock Is Up Today (Despite Its Q4 Earnings Miss) ↗

February 13, 2026

A sales partner offered a ray of hope that this company couldn't for itself.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

73 74 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.